Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Consensus Target Price from Brokerages

Structure Therapeutics Inc. (NASDAQ:GPCR) has been given an average rating of “Buy” by the eight research firms that are presently covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $81.29.

A number of equities analysts recently issued reports on GPCR shares. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. JMP Securities reiterated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. William Blair initiated coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating on the stock. Finally, Stifel Nicolaus began coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price for the company.

Structure Therapeutics Price Performance

Shares of GPCR stock opened at $19.94 on Tuesday. Structure Therapeutics has a 12-month low of $19.39 and a 12-month high of $62.74. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -26.95 and a beta of -2.37. The business has a 50 day simple moving average of $24.34 and a 200 day simple moving average of $31.35.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. On average, equities analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Structure Therapeutics in the fourth quarter valued at $3,091,000. GF Fund Management CO. LTD. acquired a new stake in shares of Structure Therapeutics during the fourth quarter worth $34,000. Woodline Partners LP lifted its holdings in shares of Structure Therapeutics by 0.7% during the fourth quarter. Woodline Partners LP now owns 333,901 shares of the company’s stock valued at $9,055,000 after purchasing an additional 2,328 shares during the last quarter. Vestal Point Capital LP lifted its holdings in shares of Structure Therapeutics by 50.0% during the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after purchasing an additional 575,000 shares during the last quarter. Finally, Twinbeech Capital LP boosted its position in shares of Structure Therapeutics by 34.3% in the 4th quarter. Twinbeech Capital LP now owns 28,268 shares of the company’s stock valued at $767,000 after purchasing an additional 7,220 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.